What is Eli Lilly's Zepbound?
Zepbound is a weight-loss medication developed by Eli Lilly and Company. It is approved for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol [1].
How does Zepbound work?
Zepbound contains tirzepatide, which is a dual agonist that activates the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors [2]. These hormones play a role in regulating appetite and blood sugar. By activating these receptors, tirzepatide helps to reduce food intake and increase feelings of fullness, leading to weight loss [3].
When was Zepbound approved?
The U.S. Food and Drug Administration (FDA) approved Zepbound for use in November 2023 [1].
What is the difference between Zepbound and Mounjaro?
Zepbound and Mounjaro both contain the active ingredient tirzepatide and are manufactured by Eli Lilly [1][4]. The primary difference lies in their approved indications. Mounjaro is approved for improving glycemic control in adults with type 2 diabetes [5], while Zepbound is specifically approved for chronic weight management in individuals who are overweight or obese [1].
What clinical trials support Zepbound's effectiveness?
Zepbound's approval was based on results from the SURMOUNT clinical trial program. In these studies, participants taking tirzepatide achieved significant weight loss compared to placebo [3]. For example, in the SURMOUNT-4 trial, individuals who continued tirzepatide treatment experienced an additional average weight reduction of 18.4% over 52 weeks [2].
What are the potential side effects of Zepbound?
Common side effects associated with Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite [1]. Serious side effects can occur, and it is important for patients to discuss any concerns with their healthcare provider [3].
What is the current patent status for Zepbound?
Information regarding the specific patent status and expiry dates for Zepbound and tirzepatide can be found on DrugPatentWatch.com [6]. Patents protect the intellectual property of the drug, influencing its market exclusivity and the potential for generic or biosimilar competition.
Who manufactures Zepbound?
Zepbound is manufactured by Eli Lilly and Company [1].
How is Zepbound administered?
Zepbound is administered as a subcutaneous injection [1]. The dosage is typically started low and gradually increased by a healthcare provider to help manage side effects [3].
What are the costs associated with Zepbound?
The cost of Zepbound can vary depending on insurance coverage and pharmacy. Eli Lilly offers a savings card program that may reduce out-of-pocket costs for eligible commercially insured patients [7].
Sources
1. Eli Lilly and Company. (n.d.). Zepbound™ (tirzepatide) Injection 5 mg, 10 mg, 15 mg, 20 mg. Retrieved from https://www.zepbound.lilly.com/
2. Eli Lilly and Company. (2023, November 8). FDA Approves Lilly's Zepbound™ (tirzepatide) Twice-Weekly Injection for Chronic Weight Management. [Press release]. Retrieved from https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-twice-weekly-injection
3. Couch, J. (2023, November 9). FDA approves Zepbound (tirzepatide) for chronic weight management. American Pharmacists Association. Retrieved from https://www.pharmacist.com/APAPressRoom/APAPressRoom/news/2023/11/09/FDA-approves-Zepbound-tirzepatide-for-chronic-weight-management
4. DrugPatentWatch.com. (n.d.). Tirzepatide [Patent Information]. Retrieved from https://drugpatentwatch.com/drugs/tirzepatide
5. Eli Lilly and Company. (n.d.). Mounjaro® (tirzepatide) Injection. Retrieved from https://www.mounjaro.com/
6. DrugPatentWatch.com. (n.d.). Zepbound [Patent Information]. Retrieved from https://drugpatentwatch.com/drugs/zepbound
7. Zepbound Savings Card. (n.d.). Retrieved from https://www.zepbound.lilly.com/savings-and-support